Eli Lilly and Company

CYRAMZA

Manufacturer:

Eli Lilly and Company

Cyramza HCPCS:

J9308

HCPCS Code Descriptor:

Injection, ramucirumab, 5 mg

Category:

J Code

Cyramza NDCs:

00002-7678-01, 00002-7669-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Cyramza:

CYRAMZA is an Oncology drug manufactured by Eli Lilly and Company and administered via the Intravenous route of administration. The J Code: J9308 is aligned to the drug CYRAMZA.

Cyramza is an injectable medication used to treat a variety of forms of cancer. Cyramza may be used to treat stomach cancer, colorectal cancer, metastatic non-small cell lung cancer, and hepatocellular carcinoma. It is type of medication known as a fully human monoclonal antibody, and it is thought to work by interfering with the growth and spread of cancer cells throughout the body. Cyramza may be given alone or in combination with other medications and is usually given after other forms of chemotherapy have proven ineffective.

ACCESS PRICING AND MORE BY REGISTERING

J9308 Added Date:

January 1, 2016

J9308 Effective Date:

January 1, 2016

J9308 Termination Date:

HCPCS Active

Cyramza billing and coding information can be found through Eli Lilly And Company at the link below:
Cyramza patient assistance information can be found through the Lilly Cares Foundation at the URL: http://www.lillycares.com
CYRAMZA prescribing information can be found at the link below:
Information regarding CYRAMZA’s side effects can be found at MedlinePlus